Genetic Background Shapes Cancer Evolution Trajectory Despite Identical Risk Factors, Landmark Mouse Study Reveals
核心洞察
An international study published in Nature demonstrates that germline genetic background profoundly dictates cancer evolution trajectory, driver mutation selection, and tumor latency in experimental liver cancer (搜索).
Researchers examined over 580 liver tumors across four genetically distinct mouse strains exposed to identical carcinogens, finding strain-specific preferences for activating mutations in Braf (搜索), Hras (搜索), Egfr (搜索), and Kras (搜索).
Highly susceptible genetic backgrounds required only a single driver event for malignant transformation, while resistant backgrounds needed multiple driver alterations and experienced early subclonal lineage loss.
An international research collaboration including the German Cancer Research Center (DKFZ) and universities of Cambridge, Edinburgh, and Yale has provided the first controlled experimental evidence that an organism's genetic makeup significantly influences how cancer develops—even when exposure to carcinogens is identical. The findings, published in Nature, offer new insights into the earliest stages of tumor development and could reshape approaches to personalized cancer medicine.
The study examined over 580 liver tumors from four genetically distinct mouse strains, with genetic differences between strains roughly corresponding to the variation observed within the human population. All animals were kept under identical conditions and exposed to the same carcinogen, diethylnitrosamine. Despite this uniformity, tumors developed along markedly different trajectories depending on genetic background.
Divergent Paths to a Common Endpoint
Although the tumors ultimately activated the same central signaling pathways—most notably the mitogen-activated protein kinase (MAPK) pathway, a multistep cascade controlling cell growth and differentiation—the genetic background decisively influenced which specific driver mutations became established. Activating mutations in Braf (搜索), Hras (搜索), Egfr (搜索), and Kras (搜索) occurred at strain-specific frequencies that could not be explained by baseline mutational spectra or transcription-coupled DNA repair.
"Cancer does not arise entirely by chance. Although tumors often reach the same biological endpoint, the path to that endpoint is decisively determined by an individual's genetic background," said Duncan T. Odom of the DKFZ, one of the study's senior authors. "Here, we were able to demonstrate for the first time the extent to which genetic background influences both the mutation processes and the pathways leading to tumor development."
Germline-Somatic Epistasis and Transformation Thresholds
The strain-specific mutation preferences stem from epistatic interactions between acquired somatic drivers and inherited genetic backgrounds. Driver mutations differentially perturbed secondary signaling pathways, including p53 cellular stress, peroxisome proliferator-activated receptor, and transforming growth factor beta pathways. This germline-somatic epistasis altered subclonal selection dynamics and dictated the number of driver hits required for oncogenic transformation.
In one particularly striking finding, highly susceptible genetic backgrounds required only a single driver event and permitted instant transformation from first-generation post-mutagenesis cells. In contrast, resistant backgrounds required multiple driver alterations and experienced substantial early subclonal lineage loss. Notably, the latency time—how quickly cancer developed—varied significantly among the four mouse strains and did not correlate with the number or type of genetic changes.
Chromosomal Stability and Whole-Genome Doubling
Genetic background also dictated chromosomal stability. Whole-genome doubling occurred exclusively in specific strains carrying Braf (搜索) mutations, correlating with shortened baseline telomeres and heightened early genomic instability. Individual host environments such as shared litters or cohousing showed no significant influence on mutagenesis or selection dynamics, further underscoring the primacy of germline genetics.
Implications for Personalized Cancer Medicine
The results suggest that even comparatively small differences in the genome can have significant effects on cancer risk, tumor biology, and possibly response to therapies. The researchers emphasize that diagnostic and therapeutic paradigms must increasingly consider how germline-somatic epistasis modifies driver gene penetrance and tumor evolution in diverse patient populations.
"This underscores how important it is to take genetic background into account when designing and interpreting biomedical and translational research," Odom added. "We therefore view our findings as an important long-term step toward even more precise, personalized cancer prevention, early detection, and treatment."